The pregnane X receptor (PXR)/steroid and xenobiotic receptor (SXR) transcriptionally activates cytochrome P4503A4 (CYP3A4) when ligand activated by endobiotics and xenobiotics. We cloned the human PXR gene and analysed the sequence in DNAs of individuals whose CYP3A phenotype was known. The PXR gene spans 35 kb, contains nine exons, and mapped to chromosome 13q11±13. Thirty-eight single nucleotide polymorphisms (SNPs) were identi®ed including six SNPs in the coding region. Three of the coding SNPs are non-synonymous creating new PXR alleles [PXR Ã 2, P27S (79C to T); PXR Ã 3, G36R (106G to A); and PXR Ã 4, R122Q (4321G to A)]. The frequency of PXR Ã 2 was 0.20 in African Americans and was never found in Caucasians. Hepatic expression of CYP3A4 protein was not signi®cantly different between African Americans homozygous for PXR Ã 1 compared to those with one PXR Ã 2 allele. PXR Ã 4 was a rare variant found in only one Caucasian person. Homology modelling suggested that R122Q, (PXR Ã 4) is a direct DNA contact site variation in the third alpha-helix in the DNA binding domain. Compared with PXR Ã 1, and variants PXR Ã 2 and PXR Ã 3, only the variant PXR Ã 4 protein had signi®cantly decreased af®nity for the PXR binding sequence in electromobility shift assays and attenuated ligand activation of the CYP3A4 reporter plasmids in transient transfection assays. However, the person heterozygous for PXR Ã 4 is normal for CYP3A4 metabolism phenotype. The relevance of each of the 38 PXR SNPs identi®ed in DNA of individuals whose CYP3A basal and rifampininducible CYP3A4 expression was determined in vivo and/or in vitro was demonstrated by univariate statistical analysis. Because ligand activation of PXR and upregulation of a system of drug detoxi®cation genes are major determinants of drug interactions, it will now be useful to extend this work to determine the association of these common PXR SNPs to human variation in induction of other drug detoxi®cation gene targets. Pharmacogenetics 11:555±572
Introduction
The nuclear hormone receptors are transcription factors regulating the induction of many genes. The pioneering work of Kliewer and Blumberg demonstrated that one member of this family, the pregnane X receptor/steroid and xenobiotic receptor (PXR/ SXR) (Blumberg et al., 1998; Lehmann et al., 1998) , encoded by NR1I2 Ã 1 (http://www.ens-lyon.fr/LBMC/ LAUDET/nomenc.html) mediates steroid and drug induction of detoxi®cation genes, including the drug metabolizing enzyme cytochrome P4503A (CYP3A4). Identical or nearly identical cDNA sequences have been cloned and termed PAR (Bertilsson et al., 1998) . More recently, another ligand activated PXR/SXR target has been identi®ed, the multidrug resistance 1 (MDR1) ef¯ux transporter that encodes P-glycoprotein (Schuetz & Strom, 2001; Synold et al., 2001) . Because CYP3A4 catalyses the oxidative metabolism of one-half of clinically administered drugs, and because Pgp ef¯uxes many drugs from human enterocytes and hepatocytes, administration of PXR ligands and subsequent induction of CYP3A4 and P-glycoprotein lead to accelerated clearance of coadministered CYP3A4 and Pgp substrates, as well as autoinduction of drug clearance, and are a major basis for drug interactions. There are numerous reports in the literature of PXR ligands, such as rifampin, causing accelerated CYP3A4 substrate clearance and requiring dose adjustments to maintain therapeutic ef®cacy (Borcherding et al., 1992) . Moreover, there is signi®cant variation among individuals in the extent to which rifampin can induce hepatic and intestinal CYP3A4 and Pgp in humans (Perry & Jenkins, 1986; Watkins et al., 1989; Kolars et al., 1992; Lown et al., 1997) . Single nucleotide polymorphisms (SNPs) in PXR may be a major contributor to the variability in response to rifampin and induction of CYP3A4 and Pgp. Indeed, while mice lacking PXR have abrogated induction of CYP3A in response to the PXR ligands dexamethasone and pregnenolone 16á-carbonitrile, these mice develop and reproduce normally (Xie et al., 2000) . These ®ndings suggest there could be normal individuals with PXR sequence variations and no overt phenotype until treated with PXR ligands.
It is also possible that sequence variations in PXR could affect basal expression of CYP3A or Pgp. There is a well-documented population variation in noninduced (basal) CYP3A activity and Pgp protein expression (Lown et al., 1997) . Moreover, the low frequency of CYP3A4 allelic variants with altered activity (Sata et al., 2000) cannot explain the extent of CYP3A variation in the population. The good correlation between hepatic CYP3A4 protein and mRNA expression suggests variation in CYP3A expression may be under transcriptional control. Because no SNPs in either the proximal or distal PXR cognate binding sequences in CYP3A4 59-¯anking regions were found when we surveyed over 300 chromosomes (Kuehl et al., 2001) , we hypothesized that sequence variations in PXR exist and could contribute to variation in expression of a target gene, CYP3A4. Although CYP3A is the sum activity of the CYP3A4 and CYP3A5 gene products in most individuals, only CYP3A4 is signi®cantly induced by PXR ligands. The CYP3A5 gene (GenBank Accession AC005020) has a consensus proximal PXRE identical to that in CYP3A4, but lacks the distal PXRE cluster found in CYP3A4, and this may be why CYP3A5 is not signi®cantly upregulated by PXR ligands.
DNA diversity in human nuclear hormone receptor transcription factors has been described and can be involved in diseases (Hughes & O'Malley, 1991; Engelkamp & van Heyningen, 1996; Meirhaeghe et al., 1998) . Indeed, sequence differences in the ligand binding domain of PXR (mouse versus human) are responsible for the species differences in induction of CYP3A4 by rifampin and certain steroids (Lehmann et al., 1998) . It is a testable possibility that sequence variations in the PXR ligand binding domain are affecting the ligand activation pro®le for human CYP3A4. Moreover, because Blumberg et al. (1998) proposed that PXR acts as a xenobiotic`sensor' to mediate the physiological response of multiple drug detoxi®cation genes that have putative PXR binding elements (Blumberg et al., 1998) , identi®cation of functional polymorphisms in PXR might explain not only variation in induction of CYP3A4 and MDR1/ Pgp, but may be more generally applicable to variation in response to PXR ligands of many drug metabolizing enzymes and transporters.
In this study, we have cloned and chromosomally localized the human PXR gene, and identi®ed SNPs within the coding region,¯anking introns, 59-and 39-UTR and promoter of PXR. PXR sequence variations were identi®ed in DNA of individuals phenotyped in vivo and in vitro for basal and rifampin inducible expression of CYP3A4 (and in some Pgp) in order to determine if there was a genotype/phenotype correlation. Finally, the functional consequences of non-synonymous changes in PXR were determined by electromobility shift assays and expression and function of PXR in transiently transfected Cos7 cells.
Methods

Cloning and sequencing the human PXR gene
The mouse PXR mRNA (AF031814) sequence was used to search the human EST database. A clone (AA679591) was selected as a probe to screen the 10X human genomics BAC library (Research Genetics, Huntsville, AL, USA). One BAC with a 150 kb insert, estimated by NotI digestion and pulse-®eld gel electrophoresis, was determined to contain the entire hPXR coding region (AF061056) by polymerase chain reaction (PCR) ampli®cation using primers for the 39-untranslated region (UTR) and the 59-UTR of hPXR. We sequenced the human PXR gene in two ways. We created plasmid subclone libraries of the B1-BAC digested with AluI, HaeIII and PstI and then selected clones for sequencing by hybridization to PXR cDNA. Because this approach will not guarantee isolation of all non-coding, intronic and upstream regions of the gene, we simultaneously pursued a BAC shotgun sequencing strategy by M13 subcloning and sequencing of a suf®cient number of randomly selected subclones. With 2 3 random shotgun sequencing and PCR directed gap closure, two contigs with perfect matches to human cDNA sequence were obtained. By combining the raw shotgun sequences from Baylor Sequencing Centre (AC069444, BAC clone RP11-169N13), a ®nal 86-kb contig was assembled which had full coverage of the entire 35 kb human PXR gene. The full gene sequence for hPXR has been deposited in GenBank (AF364606).
PCR assays and direct sequencing of PXR exons and anking introns in human genomic DNA PCR assays were designed in order to sequence the entire coding region, the 59 and 39-UTR regions and approximately 50 bp intronic sequences¯anking each exon and about 600 bases of the promoter. PCR primers were designed with PRIMER3 (http:// www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi) ( Table 1) . Universal M13±28 (AGGAAACAGCTAT GACCAT) and -40 (GTTTTCCCAGTCACGACG) primer tails were attached to the 59 end of the PCR primers for convenience in direct sequencing of the PCR product. PCR was preformed on a DNA engine tetrad (MJ Research Inc., Watertown, MA, USA) with the following cycle conditions: 92 8C for 15 s; 30 cycles of 92 8C for 10 s, annealing temperature 30 s, 72 8C for 1 min; followed by 72 8C for 10 min. PCR reactions were carried out with High Fidelity Expand PCR system or High Fedelity GC-rich system (Roche, Nutley, NJ, USA) in the following ®nal conditions in a total reaction volume of 25 ìl: 1 3 buffer with MgCl 2 , 0.2 mM dNTP, 5 pmol forward and reverse primer each, 1 U of polymerase and 50 ng of template DNA. We removed unincorporated nucleotides and primers by incubating the PCR product with shrimp alkaline phosphatase and exonuclease for 30 min at 37 8C followed by 15 min at 80 8C (Nickerson et al., 1997) . PCR products were sequenced with M13-28 and -40 primers from both ends to achieve 2 3 coverage by standard dye-terminator sequencing procedure on either ABI 377 or ABI 3700 sequencers. The resultant trace ®les were base-called by phred and assembled by phrap (http://www.genome.washington. edu). Polyphred (Nickerson et al., 1997) was used to detect potential heterozygosity. To be a`true' variant in a sample, the variant site base call generated from the forward read had to be identical to that generated by the reverse read. In some samples SNPs were called with reads from only one direction when true SNPs are called from both directions in other samples at the same site. All SNP calls were independently inspected by two technicians.
Multiple sequence alignment and homology modelling BLASTP search against the non-redundant protein database (http://www.ncbi.nlm.nih.gov) was conducted with default parameters using human PXR protein sequence as a query. Twenty protein sequences sharing high similarity to human PXR were chosen for a multiple sequence alignment using Wisconsin Package software (Genetics Computer Group, Madison, WI, USA). Homology modelling of PXR DNA binding domain (DBD) was performed with SWISS-MODEL server. Because of its 42% identity to PXR DBD, thyroid hormone receptor DBD was used as a template to generate a model for PXR amino acids 38±138.
Population samples DNA samples were obtained from the following sources and grouped as follows: (group 1) 20 Caucasian human livers whose midazolam 19-hydroxylase and 4-hydroxylase activities and CYP3A5 and CYP3A4 protein were characterized (University of Washington, University of Pittsburgh, the Medical College of Virginia and St Jude Children's Research Hospital); (group 2) 25 subjects (representatives of seven families) whose nifedipine clearance had been determined (University of Newcastle upon Tyne, UK); (group 3) 10 subjects (Caucasians, African Americans and Asians) whose intestinal CYP3A4 and MDR1 mRNA content had been determined before and after two days of rifampin treatment (University of Michigan); (group 4) primary human hepatocytes from nine Caucasian people whose basal and rifampin-inducible testosterone 6â-hydroxylase activity had been characterized in culture (University of Pittsburgh); (group 5) 14 subjects (Caucasians, African Americans, Asians and Hispanics) whose hepatic CYP3A4 inducibility phenotype had been determined by using the erythromycin breath test at baseline and again following treatment for 1 week with rifampin (University of Michigan); a poor nifedipine metabolizer (PM) and four other family members (University of Michigan).
PXR genotype was also determined in DNA from the kidneys from 12 people phenotyped for midazolam 19-hydroxylase activity (Indiana University). All DNAs were obtained from individuals phenotyped for CYP3A activity. An additional 18 African American liver samples were assayed for their hepatic CYP3A4 level by western blot and genotyped at two of the SNP sites (P27S and G36R). Informed consent was obtained from all individuals and approval of this research was obtained according to the relevant institutional guidelines.
Western blot analysis
We performed quantitative immunoblotting of CYP3A4 content of tissue preparations as described (Paine et al., 1997) ; puri®ed cDNA-expressed CYP3A5 (a gift from Dr Raimund Peter, University of Washington) was the reference standard (Paine et al., 1997) . Liver microsomes (10±20 ìg) prepared from liver tissue (Paine et al., 1997) were resolved by electrophoresis and CYP3A4 was detected with anti-CYP3A4 antibody (Paine et al., 1997) . We determined the integrated optical density of each CYP3A4 band using a Bio-Rad ChemiDoc (BioRad, Hercules, CA, USA) and Quantity One program. Human PXR was detected on immunoblots of in-vitro transcribed and translated PXR alleles (2 ìl) or total cell lysate (20 ìg) from Cos-7 cells transiently transfected with various PXR alleles. Human PXR was identi®ed using a 1 : 100 dilution of polyclonal goat anti-human PXR antibody [PXR (N-16); Catalog c-9690; Santa Cruz Biotechnology, Inc.; Santa Cruz, CA, USA]. The primary antibody was followed with a 1 : 10000 dilution of an anti-goat IgG peroxidase conjugate antibody (Sigma, St Louis, MO, USA) and developed with the enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL, USA).
Site-directed mutagenesis pSG5-hPXRÄATG (PXR Ã 1) was generously provided by Dr Kliewer (Lehmann et al., 1998) . Mutant proteins corresponding to the three coding variations
were created directly from the pSG5-hPXRÄATG plasmid by PCR with a mutant primer and the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The PXR variant alleles were sequenced to con®rm base changes.
Electrophoretic mobility shift assay PXR Ã 1, PXR Ã 2, PXR Ã 3 or PXR Ã 4 and RXR-apha, were each in-vitro transcribed and translated using a TNT-Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Double-stranded, 32 P-labelled oligonucleotides (400 000 c.p.m. of the labelled double-stranded oligonucleotide per reaction) representing the CYP3A4 PXR DNA binding sequence, an everted repeat with six basepair spacer (ER6) ER6 59-GATCAATATGAACTCAAAGGAGGTC AGTG-39 or a mutant ER6 (mtER6) 59-GATCAATAT GAACTCAAAGGAATACAGTG-39 (mutated/underlined bases disrupt NHR binding half-site) were incubated with 10 mM Tris (pH 8.0), 40 mM KCl, 0.05% NP-40, 6% glycerol, 1 mM DTT, 0.2 ìg poly (dI-dC), and 2.5 ìl of RXR and PXR in-vitro transcribed and translated protein (Lehmann et al., 1998) . Reactions were set up in the absence or presence of 50, 100 or 500 molar excess unlabelled ER6 or 500X mtER6 for competition. Complexes were resolved by electrophoresis through a nondenaturing 4% polyacrylamide gel and analysed on phosphorimager.
Preparation of the CYP3A4 promoter luciferase reporter construct The CYP3A4 proximal promoter region (À1084/ 53) was ampli®ed from genomic DNA by long PCR (Expand Long Template PCR System, Roche) using primers described by and 59-CATTGCTGGCTGAGGTGGTT-39) (Goodwin et al., 1999) . The PCR product was digested with BglII and BamHI and the (À362/53) fragment was retrieved by gel cleaning (Qiaex II, Qiagen Inc., Valencia, CA, USA) and then cloned into the BglII site in pGL3B (Promega). The CYP3A4 distal xenobiotic response element (PXRE) (À7836/À7208) was ampli®ed from genomic DNA by PCR (AmpliTaq, Roche) using primers 59-TATTCTAGAGAGATGGTTCAT-39 and 59-TCTAGATCTCGTCAACAGGTT-39. The distal PXRE PCR product was initially cloned into pCR2.1-TOPO (Invitrogen, San Diego, CA, USA) and a clone with the insert in the desired orientation was de®ned by SpeI digest. The distal PXRE insert was then directionally subcloned into the KpnI and XhoI sites in CYP3A4 (À362/53)/pGL3B vector and the resultant promoter construct [p3A4-362 (À7836/ À7208ins)] was sequence veri®ed and used in transfection experiments.
Transient transfection of PXR alleles
Cos-7 cells were cultured in DMEM (Gibco BRL, Life Technologies, Rockland, MD, USA) supplemented with 10% fetal calf serum and 1% antibiotic solution and maintained at 37 8C. The cells (2 3 10 5 per 3.8 cm 2 well) were plated on day 1, cotransfected on day 2 with 3 ìl lipofectamine (Life Technologies) 75 ng CYP3A4-PXRE-LUC reporter plasmid, 25 ng of pSG5-hPXRÄATG (PXR Ã 1) or the PXR variant alleles and 30 ng of pRL-TK (Renilla Luciferase, Promega). Control wells were transfected with pSG5 instead of PXR expression plasmids. Cells were washed with medium after 18 h and incubated with fresh medium containing various concentrations of rifampin (1À300 ìM) for an additional 18 h. Cells were harvested and Dualluciferase activities were determined (Thottassery et al., 1999) according to manufacturer's instructions (Promega) and CYP3A4 luciferase activity was normalized to TK Renilla luciferase activity.
Results
Genomic structure of the PXR gene
The human PXR gene (GenBank Accession AF364606), encoding the hPXR mRNA (AF061056), consists of nine exons; exon 2 through exon 8 contain the coding region of 434 amino acids ( Fig. 1 ). Exon/intron boundaries (Table 2) were determined by a combination of aligning the cDNA sequence to genomic sequence and splice site prediction (http://www.fruit¯y.org/seq_tools/splice.html).
An hPAR2 (PXR/SXR) cDNA sequence reported by Bertilsson et al. (1998) (AF084644) has a different 59-sequence compared to either hPXR (Lehmann et al., 1998) or hSXR (Blumberg et al., 1998) and is predicted to be 39 amino acids (117 nt) longer at the amino terminal end in translation product. Comparison of the upstream 117 nt from the PAR sequence against the NCBI human EST database did not identify any clones with the additional 59 sequence. However, when hPAR2 is aligned to the hPXR genomic sequence, the unique sequence at the 59 end of hPAR2 was identical to a region in intron 1. This suggests that the hPAR2 mRNA record is correct and hPAR2 possesses an alternatively spliced ®rst exon. Moreover, previous studies on human PXR have revealed multiple transcripts of different sizes (3.5 kb, 5.2 kb and 6.5 kb) with the 3.5 kb mRNA the major transcript in human liver and intestine. Similar to mouse PXR.1 mRNA, which has an alternatively spliced form in the ligand-binding domain resulting in a deletion of 41 amino acids (mPXR.2), the human PXR major transcript (hPXR.1) also has an alternatively spliced form (hPXR.2) (Dotzlaw et al., 1999) . The hPXR.2 spliced variant arises from a deletion of 111 bp from the ®rst half of exon 5 (Table  2 ) due to preferential usage of a cryptic splice acceptor site within exon 5.
Mapping the human PXR gene
We have placed the PXR on a physical map of the genome by using STSs designed from the cDNA to score the GeneBridge4 (GB4) radiation hybrid (RH) panel. The PXR gene maps to chromosome 3q11±13 and the closest STS markers are WI-9270, CHLC.GA-TAG01.125, SGC32480 and TIR-A002L11. Chromosomal assignment was con®rmed with FISH analysis by co-hybridization of a labelled B1-BAC probe and a biotinylated chromosome 3 cM speci®c probe (DZ31) to normal metaphase chromosomes derived from PHA-stimulated peripheral blood lymphocytes. Band assignment, made by conducting fractional length measurements, placed the PXR at an area corresponding to chromosome 3q13±21. (Fig. 2) .
Single nucleotide polymorphisms identi®ed
We genotyped DNA from individuals phenotyped for CYP3A expression, since we reasoned the outliers in CYP3A phenotype would be the most likely to have functional defects in PXR. A total of 38 SNP sites were identi®ed (Table 3) . PXR nucleotide diversity in Americans of European descent and Europeans (here- after collectively referred to as Caucasians) is 6.3 3 10 À5 (1 in 15 984 bp) in the coding region, 1.64 3 10 À3 (1 in 609 bp) in the 59 and 39 UTR region, 5.83 3 10 À4 (1 in 1715) in the intronic region, and 6.62 3 10 À4 (1/1510) in the upstream region. Most of the SNP sites have a minor allele frequency of less than 0.1. At all sites, the genotype frequencies do not signi®cantly differ from HardyWeinberg equilibrium. ( P . 0.05). The allele frequency difference between Caucasian and African American samples was not calculated because of the small sample size of African Americans. Three out of the six coding variations cause non-synonymous changes in the protein sequence of the reference allele NR1I2 Ã 1/PXR Ã 1. A 79C to T transition (NR1I2 Ã 2/PXR Ã 2) and 106G to A transition (NR1I2 Ã 3/PXR Ã 3) lead to amino acid substitutions at codon 27 (Pro 27 Ser) and codon 36 (Gly 36 Arg), respectively. The frequency of PXR Ã 2 and PXR Ã 3 alleles was greater in African Americans (f 0.2 and 0.03, respectively) than in Caucasians (f 0.00, f 0.01). For all the samples screened, only one Caucasian person was heterozygous for a 4321G to A transition (NR1I2 Ã 4/PXR Ã 4) leading to an amino acid change of arginine (R) 122 to glutamine (Q), and no individuals were homozygous for this allele. Reference and variant genomic sequences were used to predict splice sites in order to evaluate potential splice site variants. Only the C to G8357 SNP creates a cryptic splice site (cttca[C/G]ttccc) with a splice prediction score of 0.98. Only two heterozygous individuals were found in the study populations. One person with the C to G8357 SNP had a low hepatic CYP3A4, but RT-PCR of the entire hPXR cDNA from this hepatic RNA failed to reveal any aberrant PXR splicing.
SNPs were identi®ed in the promoter of PXR. A database search for transcription factor binding sites revealed that some of these SNPs are located within potential cis-acting elements (Table 3) . For example, the SNP at À24719 lies within a potential binding site for the progesterone receptor; the SNP at À24756 lies within consensus elements for c/EBP and HNFÀ1A (hepatic nuclear factor 1A); the SNP at À25385 is within a NF-Kâ consensus sequence; and the À25564 SNP is located within a putative binding site for heat shock transcription factor (HSTF).
The human PXR gene, like the mouse gene, has alternative splicing in exon 5 that yields two slightly different ligand binding domains. These are hPXR.1 and hPXR.2 (lacking 37 amino acids in exon 5). There were no SNPs at the splice junctions in exon 5. Data mining of the human EST database reveals one apparent genetic polymorphism. Compared to the reference PXR (also known as PAR alleles) the (Blumberg et al., 1998) has sequence differences in the ligand binding domain, including a frame shift that changes 19 amino acids, but this sequence was never found in any persons. In GenBank reports (AJ009936, AJ009937 and AY007189), two alternatively spliced PXR variants are described that result from use of alternative translation initiation codons. hPRR1C and 2C are 23 amino acids longer and hPRR2B is 56 amino acids shorter at the amino terminal end compared to PXR. Although these could result from alternative promoter usage, we found no SNPs within 30 bp of any of the putative alternative transcription start sites that would, presumably, alter their usage.
In-vivo correlation PXR Ã 4 was found in only a single Caucasian individual who had been CYP3A phenotyped using the erythromycin breath test (Fig. 3, #f03) . The mean erythromycin breath test values (% administered 14 C exhaled in 1 h) before and after rifampin treatment were 2.01 and 4.18, respectively, among 14 individuals, while the erythromycin breath test values in the person heterozygous for PXR Ã 4 were 2.71 and 4.23 before and after rifampin, respectively. The frequency of individuals with a single PXR Ã 3 allele ranged from 1% in Caucasians to 3% in African Americans, and the frequency of the PXR Ã 2 (P27S) allele ranged from 0% in Caucasians to 20% in African Americans (Table 3) . We genotyped for PXR Ã 2 and PXR Ã 3 using DNA from 18 additional African Americans, who had been phenotyped for hepatic CYP3A4 immunocontent. No additional individuals with the PXR Ã 3 allele were identi®ed and no African Americans homozygous for PXR Ã 2 were identi®ed.
To determine the relationship between the PXR Ã 2 (P27S) genotype and CYP3A phenotype, two statistical analyses were undertaken. We compared the mean level of immunoreactive hepatic CYP3A4 (excluding CYP3A5) in all heterozygous individuals (PXR Ã 1/ Ã 2, n 8) to all (Caucasians and African Americans) homozygous individuals (PXR Ã 1/ Ã 1, n 30). The appropriate test was the t-test for comparing two groups with unequal ( P 0.0137) variances. There was no difference in the mean value of the CYP3A4 phenotype ( P 0.772) between all individuals homozygous for PXR Ã 1/ Ã 1 or heterozygous for PXR Ã 1/ Ã 2. A second analysis further divided the homozygous PXR Ã 1/ Ã 1 individuals according to ethnicity (Caucasian, n 20 and African American, n 10). An analysis of variance (ANOVA) among the three groups indicated no difference ( P 0.541) in the distribution of CYP3A4 content among Caucasians with PXR Ã 1/ Ã 1 genotype or African Americans with PXR Ã 1/ Ã 1 or PXR Ã 1/ Ã 2 genotypes. Furthermore, when the mean CYP3A4 hepatic content was compared between African Americans homozygous for PXR Ã 1 or heterozygous for PXR Ã 1/ Ã 2 no signi®cant difference was found ( P . 0.2). A comparison of the mean CYP3A4 between Caucasians and African American individuals homozygous for PXR Ã 1 was not signi®cantly different ( P . 0.15).
We next determined the association of each of the PXR alleles to CYP3A phenotypes determined in vivo by nifedipine clearance or for basal or rifampininducible erythromycin N-demethylation by the erythromycin breath test or in-vitro by assays for total midazolam hydroxylation or for basal or rifampin- (AF061056), and the base immediately 59 to 1 is ±1. SNP positions in the coding region are numbered in bold. Light grey squares are homozygous major alleles at any particular SNP site, dark grey squares are heterozygous, black squares are homozygous minor alleles. White squares are data not available. The x-axis are the patient identi®cation numbers for internal use. Those patients with boxed numbers carry the CYP3AP1 Ã 1 allele, which is associated with high levels of CYP3A5 protein (Kuehl et al., 2001) . (b) Genotypes for the CYP3A4 Ã 1B (±288, NFSE) (Rebbeck et al., 1998) and CYP3AP1 (±44) (Finta & Zaphiropoulos, 2000) alleles. Light grey squares are homozygous for CYP3A4 Ã 1B or CYP3AP1 Ã 3, dark grey squares are heterozygous CYP3A4 Ã 1/ Ã 1B and CYP3AP1 Ã 3/ Ã 1, black squares are homozygous CYP3A4 Ã 1B and CYP3AP1 Ã 1. (c) CYP3A phenotypes. The y-axis represents CYP3A phenotypic measurements. Patient treatments are described in detail in Methods. All individuals within each group are sorted from low to high CYP3A expression.
inducible testosterone 6â-hydroxylase activity (Figs 3 and 5) . A comparison of PXR genotype and corresponding CYP3A phenotype showed a correlation with two polymorphisms, a À25385C to T transversion in the promoter and a À24113G to A transition in intron 1. Those individuals homozygous for the À25385T allele and the À24113A allele had approximately two-fold higher erythromycin breath test values after rifampin treatment and a correspondingly higher fold induction of the ERMBT by rifampin compared to those homozygous for À25385C or À24113G alleles (Fig. 5 ) with a sign®cance of P 0.05. A 7635A to G transition in intron 5 was associated with higher magnitude of induction of intestinal CYP3A by rifampin with a signi®cance of P 0.0159. Persons homozygous for the 7635G allele had two-fold higher induction of CYP3A compared to those homozygous for 7635A. An 8055C to T substitution was also associated with intestinal CYP3A inducibility phenotype. Persons carrying at least one T allele had two-fold higher levels of intestinal CYP3A following rifampin treatment compared to individuals homozygous for the 8055C allele with a signi®cance of P 0.044. Two polymorphisms in the 39-UTR, 10620C to T and 10799G to A showed that primary human hepatocytes from individuals carrying at least one 10620T allele or one 10799A allele were associated with two-fold lower testosterone 6â-hydroxylase activity following treatment with rifampin compared to those homozygous for C10620 or G10799 (Fig. 5) . 39-UTR SNPs 11156A to C and 11193T to C showed that those people heterozygous with at least one 11156C or one 11193C allele had 1.45-fold lower P-glycoprotein levels in gut biopsies compared to those with homozygous 11156A and 11193T alleles ( P 0.071 and P 0.0556, respectively).
The À25564G to A PXR promoter SNP was found in two individuals for which CYP3A phenotype was available (Fig. 3) . One person with a À25564A allele was at the lowest extreme for hepatic CYP3A4 expression (immunocontent and midazolam hydroxylase activity). The mean CYP3A4 content among human livers homozygous for the À25564G allele was 52.1 AE 37.1 nmol/mg microsomal protein, the person with the À25564G/A genotype had 5 nmol CYP3A4/mg microsomal protein. The other person carrying a À25564A allele had the lowest nifedipine clearance. However, the À25564A allele was not found in other poor nifedipine metabolizers or in other human livers examined, including 23 additional African American livers screened. The À25564A allele was found in DNA from two African Americans in which renal midazolam hydroxylase activity was measured (not shown). However, because CYP3A4 is not signi®cantly expressed in human kidney, no genotype/phenotype correlation could be made.
Homology model
To evaluate the functional signi®cance of the amino acid substitutions, the regions of the human PXR AF-1 region (amino acids 1±40) and DNA binding domains (amino acids 41±140) (Lehmann et al., 1998) containing the non-synonymous amino acid changes were aligned with the AF-1 and DNA binding domains of the 20 most closely related protein sequences in the nuclear receptor family (Fig. 6) . Sequence homology suggested that the constitutive androstane receptor (CAR) family and the vitamin D receptor family are the most closely related nuclear hormone families, while members of the thyroid hormone receptor, retinoid acid receptors, peroxisome proliferator activator receptors and the liver X receptor are more distant to PXR. Pro 27 and Gly 36 reside in a less conserved region in the AF-1 amino terminal region of the protein. The proline to serine amino acid 27 change could affect the hydrophobicity of this amino acid position as proline contains an aliphatic nonpolar R group, while serine contains an uncharged polar hydroxyl R group. The change of Gly 36 to Arg 36 will change the charge of this amino acid because glycine is neutral while arginine is highly positively charged. Protein phosphorylation prediction analysis predicted that the 27S creates a putative serine phosphorylation site (VPGKSSVNA, serine prediction score 0.962 (using the NetPhos 2.0 Prediction Server, http://www. cbs.dtu.dk/services/NetPhos/). Arg 122 is located in the DNA binding region of PXR and Arg 122 is well conserved among the 20 family members aligned, the only substitution residue at this position among related nuclear hormone receptors being lysine, an amino acid with similar charge and polarity. The substitution of an arginine to glutamine R122Q would change a basic amino acid to an uncharged amino acid, potentially altering DNA binding.
To begin predicting the functional consequence of the three non-synonymous coding changes, amino acids 38±148 encompassing the DNA binding domain of PXR were modelled based on the crystal structure of the thyroid hormone receptor-RXR complex binding to DNA (Fig. 7) . The thyroid hormone receptor DNA binding domain (DBD), which is 45% identical to the PXR DBD, was selected as a template. Based on the structure and functional features on the TR DBD (Rastinejad et al., 1995) , Arg 122 was modelled to a site in one alpha helix portion of the DBD (A-helix). The substitution to a glutamine could affect the interaction with DNA because it is in a position that should directly interact with DNA.
Functional consequence of PXR variant alleles to transcriptional activation of CYP3A We used site-directed mutagenesis to generate PXR Ã 2, Ã 3 and Ã 4 from the PXR Ã 1 plasmid. The plasmids were in-vitro transcribed and translated in the presence of 35 S methionine followed by PAGE and PhosphorImage analysis. Equivalent rates of denovo synthesis and translation rates were observed for each of the PXR proteins (not shown). Subsequent immunoblot analysis of the in-vitro transcribed and translated PXR Ã 1, Ã 2, Ã 3 and Ã 4 proteins revealed similar amounts of protein (Fig. 8a) . The PXR Ã 1, Ã 2, Ã 3 and Ã 4 proteins were used in electrophoretic mobility shift assays (EMSAs) with RXRalpha together with the PXR DNA binding element (PXRE) in CYP3A4 (an ER6) oligonucleotide or a mutant ER6 oligonucleotide. PXR Ã 3 and PXR Ã 2 proteins showed slightly greater amounts of PXRE±PXR±RXR complex compared to PXR Ã 1 protein (Fig. 8b) . However, the amount of PXR Ã 4±RXR±PXRE complex formed was 84±96% less than the amount of complex formed by any of the other PXR alleles. This difference in binding af®nity could result in a difference in transcriptional activation of CYP3A4 by PXR Ã 4. The percentages of PXR bound in the absence versus the presence of increasing amounts of PXRE competitor were determined. Direct comparison of competition ef®ciency at equivalent concentrations of PXRE competitor revealed no signi®cant difference between the PXR Ã 1, PXR Ã 2 or PXR Ã 3 proteins in the displacement by excess unlabelled PXRE. None of the PXR proteins complexed to the PXRE-ER6 were completed with 500X excess unlabelled mutant ER6.
To evaluate the effect upon transcription of the PXR non-synonymous variants, we transiently transfected Cos-7 cells with a luciferase reporter containing the distal and proximal CYP3A4 PXREs, with or without the reference or variant PXR alleles and with and without rifampin treatment (Fig. 9a) . The dose± response of rifampin activation of the CYP3A4 PXREs by PXR Ã 1, PXR Ã 2 and PXR Ã 3 was similar. Rifampin activation by PXR Ã 4 was signi®cantly attenuated 32 P-labelled CYP3A4 PXRE (ER6) oligonucleotide was incubated with PXR Ã 1, PXR Ã 2, PXR Ã 3, PXR Ã 4 along with RXR-alpha in the absence (no competitor) or presence of unlabelled ER6 (50±500-fold excess) or unlabelled mtER6 (500-fold excess). After electrophoresis, complex formation was assessed by a phosphoimager or mutant PXRE (mtER6).
relative to the other PXR alleles. The cell lysates analysed for reporter activity were simultaneously analysed on immunoblots for expression of hPXR protein. The amount of PXR protein was identical in cells transfected with each of the PXR alleles (Fig.  9b) ; thus the differences between the alleles in activation of the CYP3A4 PXREs were due to differences in binding and transcriptional activation of the CYP3A4 promoter and not due to differences in the amount of PXR protein produced in cells transfected with different PXR alleles.
Discussion
The clinical signi®cance of variations in CYP3A-mediated metabolism is realized as major effects on drug ef®cacy, drug toxicity and, hence, therapeutic outcome. The PXR/SXR nuclear hormone receptor serves to relay drug and steroid signals to induce CYP3A. Because PXR regulates CYP3A4, we tested the hypothesis that sequence variation [SNPs, insertions, deletions and microsatellite polymorphisms] in PXR are associated with clinically signi®cant variation in both inductive and constitutive CYP3A4 expression.
We sequenced the human PXR gene and found that it has nine exons, with hPXR encoded by eight exons (exons 2±9). The PXR gene is localized on chromosome 3q11±13. We identi®ed 38 SNPs in the gene and determined their allelic frequencies among Caucasians and African Americans. Three synonymous and three non-synonymous changes were detected. The non-synonymous changes encoding PXR Ã 2, Ã 3 and Ã 4 were located in exons 2 and 4. The PXR Ã 2 and PXR Ã 3 alleles were more frequent in African Americans compared to Caucasians. PXR Ã 2 (P27S) and PXR Ã 3 (G36R) polymorphisms were localized in the activation domain-1 (AF-1) region of PXR. The AF-1 region in some nuclear hormone receptors can act in a ligand independent fashion and interact with the AF-2 domain (Heuman et al., 1982) , a domain that frequently interacts with coactivators. However, our transfection results suggest that amino acid changes in the AF-1 region of PXR did not alter the extent to which PXR could transcriptionally upregulate the CYP3A4 promoter in response to rifampin treatment. It remains to be determined, however, whether the putative serine phosphorylation site created by the P27S amino acid change in the AF-1 domain alters PXR activity in response to any relevant serine kinases.
The frequency of sequence variations in PXR will be a useful contribution to the human polymorphism database in establishing the patterns of variations and linkage disequilibrium in the human genome. Moreover, because PXR contains several domains (ligand binding, DNA binding, dimerization) that are presumably under different selective pressures, our results may also shed light on evolutionary constraints on intragenic sequence variation in genes that encode multi-domain transcription factors. When both synonymous and non-synonymous variations are combined, the total nucleotide diversity in the AF-1 domain is 1 in 4439 bp; in the DNA binding domain is 1 in 22 053 bp and in the ligand binding domain is 1 in 21 607 bp. Intriguingly, we only found non-synonymous sequence variations in the AF-1 domain of PXR, and only a single person heterozygous for a cSNP in the DNA binding region of PXR. Despite the fact that there is signi®cant sequence variation between species in the ligand binding domain of PXR, our screen of almost 200 chromosomes failed to ®nd a single PXR gene with SNPs in this region. Previous comprehensive analysis of the frequency of nucleotide diversity in human vector and pRL-TK. Cells were cultured in the absence or presence of rifampin. Cell extracts were subsequently dual assayed for ®re¯y luciferase (CYP3A4 promoter activity) and renillin luciferase (TK vector control), CYP3A4-LUC activity was ®rst normalized to renillin luciferase activity. The rifampin treated CYP3A4-LUC activity was then divided by non-drug treated CYP3A4-LUC activity and the results expressed as fold increase over untreated control subjects. Each bar indicates the mean of six replicate determinations from a single experiment and is representative of results from at least three independent experiments. (b) Cell lysates from three replicates/treatment group were pooled and 20 ìg of these cell lysates was assayed for hPXR protein expression on immunoblots.
genes reported a nucleotide diversity of approximately 1 in 2000 bp of noncoding DNA and lower frequencies in coding sequences (Cargill et al., 1999; Halushka et al., 1999) . The nucleotide diversity in our study population is 1 in 998 bp in UTRs and 1 in 1832 bp in introns, which is not signi®cantly different from reports from other genes. The lower degree of variation in PXR (nucleotide diversity of 1 in 15 984 bp of coding sequence in Caucasians) may re¯ect an important function of this gene (and its targets). In this regard, it is of interest that, in our recent analysis of sequence diversity in the CYP3A4 promoter in which we analysed over 300 chromosomes, we failed to ®nd any SNPs in either the cognate distal or proximal PXR binding motifs, suggesting an important role for this transcription factor in CYP3A4 regulation.
CYP3A inductive phenotype
Because induction of CYP3A4 mRNA following treatment with rifampin, phenobarbital or dexamethasone always means increased protein and increased activity, phenotype can substitute reasonably for CYP3A4 gene transcription, and allows for PXR genotype/ CYP3A4 inductive phenotypes to be compared. While there is unlikely to be any assay which is a pure probe of PXR phenotype, a strong association is likely to exist between PXR genotype and the extent of CYP3A4 or MDR1/Pgp induction by PXR ligands such as rifampin. Indeed, the phenotypic importance of PXR sequence variation may only be seen under inductive pressures. However, to our knowledge, the area of inducibility polymorphisms has not been well investigated in vivo. We took advantage of several unique cohorts of individuals phenotyped for the magnitude of CYP3A4 induction known to be mediated by PXR; rifampin induction of hepatic CYP3A4 was measured by the erythromycin breath test; rifampin induction of intestinal CYP3A4 and Pgp mRNAs were measured in human gut biopsies; rifampin induction of testosterone 6â-hydroxylase activity was measured in primary human hepatocytes. We also assembled cohorts of genomic DNA from populations phenotyped in vivo for basal CYP3A activity using the substrate nifedipine or in vitro in human liver samples using the substrate midazolam. Indeed, an important feature of our study design is that we did not use a single selected trait measurement of CYP3A4 levels, but used samples from individuals phenotyped by a variety of CYP3A noninvasive assays because of the non-concordance among all non-invasive CYP3A assays. Although our study populations are small, these unique established groups of CYP3A phenotyped humans (cohorts that would otherwise require many years to assemble) allowed us to move immediately and rapidly forward in testing our hypothesis. We found some associations of PXR genotype and CYP3A phenotype. Several silent polymorphisms in intronic regions of PXR and several promoter SNPs were correlated with CYP3A inductive phenotype in vitro and in vivo. However, because of the large number of statistical tests performed, the type I error rate is in¯ated, and many of the P-values would not be signi®cant after being rigorously adjusted for the number of tests. Likewise, true correlations might have gone undetected in our analyses. Nevertheless, these preliminary results still provide suggestions for future, larger, designed studies with suf®cient power to con®rm these associations.
Signi®cance of PXR polymorphisms
The extent to which drugs, such as rifampin, can ligand activate PXR and upregulate CYP3A is of importance because rifampin is coadministered with so many drugs that are CYP3A and MDR1/Pgp substrates and thus contributes to increased or decreased effectiveness of these drug therapies, as well as adverse side-effects (Borcherding et al., 1992) . In addition, CYP3A induction could enhance bioactivation of environmental chemicals. Some environmental contaminants, such as polychlorinated biphenyls, are potent activators of PXR (Schuetz et al., 1998) and inducers of the endogenous CYP3A protein (Schuetz et al., 1986) . CYP3A is also involved in the bioactivation of several carcinogens (Lewis et al., 1998) . Thus, variation in PXR and hence CYP3A expression could be a risk factor for toxicities from these agents in individual subjects. Moreover, the signi®cance of human variation in PXR is likely to be more generally applicable to interindividual variation in induction of other drug detoxi®cation proteins, and ultimately drug response because (i) PXR ligands upregulate other CYP450s, phase II enzymes and drug ef¯ux transporters (Meehan et al., 1988; Schuetz et al., 1988; Zhou et al., 1990; Bachmann & Jauregui, 1992; Shaw et al., 1993; Schuetz et al., 1996; Strom et al., 1996; Feng et al., 1998; Honkakoski & Negishi, 1998) and (ii) consensus PXR binding motifs have been identi®ed in the 59-¯anking sequences of some of these genes (Blumberg et al., 1998) . Finally, because activation of PXR appears distinct from any other hormone receptors identi®ed, it has been suggested that PXR de®nes a novel endocrine signaling pathway important for regulation of both steroid hormone and sterol homeostasis . Indeed, some of the most ef®cacious activators of PXR are endogenous steroids (Blumberg et al., 1998) and, recently, PXR was shown to have a role as a bile acid sensor (Staudinger et al., 2001 ). Variability at the PXR genetic locus may therefore be associated with physiological, and perhaps pathophysiological, changes in steroid, cholesterol or bile acid levels. Indeed, the phenotype of hepatomegaly, growth retardation and histological liver disease in transgenic mice expressing constitutively active hPXR suggests that sequence variations or physiological conditions leading to constantly active PXR could be associated with hepatic disease.
